Improvement in Gonadotropin Secretion after Corticosteroid Therapy in a Case of POEMS Syndrome.

Sasano, Tetsuo; Sakurai, Shinichi; Hara, Yuki

doi:10.1507/endocrj.45.413

Cited by 6 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…19 Primary and secondary hypothyroidism, hypogonadism, adrenocortical insufficiency, and diabetes mellitus have been described. 19,22,86,97,115,116 Parathyroid hormone abnormalities were found in 4 of our patients and have been reported previously. 2,100,117,118 Papilledema, which occurs in 29% to 55% of patients, may be asymptomatic or may cause headache, transient obscurations of vision, scotomata, enlarged blind spots, or progressive constriction of the visual field.…”

Section: Clinical Featuressupporting

confidence: 86%

POEMS syndrome: definitions and long-term outcome

Dispenzieri

Kyle

Lacy

et al. 2003

Blood

712

806

View full text Add to dashboard Cite

The POEMS syndrome (coined to refer to polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes) remains poorly understood. Ambiguity exists over the features necessary to establish the diagnosis, treatment efficacy, and prognosis. We identified 99 patients with POEMS syndrome. Minimal criteria were a sensorimotor peripheral neuropathy and evidence of a monoclonal plasmaproliferative disorder. To distinguish POEMS from neuropathy associated with monoclonal gammopathy of undetermined significance, additional criteria were included: a bone lesion, Castleman disease, organomegaly (or lymphadenopathy), endocrinopathy, edema (peripheral edema, ascites, or effusions), and skin changes. The median age at presentation was 51 years; 63% were men. Median survival was 165 months. With the exception of fingernail clubbing (P ‫؍‬ .03) and extravascular volume overload (P ‫؍‬ .04), no presenting feature, including the number of presenting features, was predictive of survival. Response to therapy (P < .001) was predictive of survival. Pulmonary hypertension, renal failure, thrombotic events, and congestive heart failure were observed and appear to be part of the syndrome. In 18 patients (18%), new disease manifestations developed over time. More than 50% of patients had a response to radiation, and 22% to 50% had responses to prednisone and a combination of melphalan and prednisone, respectively. We conclude that the median survival of patients with POEMS syndrome is 165 months, independent of the number of syndrome features, bone lesions, or plasma cells at diagnosis. Additional features of the syndrome often develop, but the complications of classic multiple myeloma rarely

show abstract

Section: Clinical Featuressupporting

confidence: 86%

POEMS syndrome: definitions and long-term outcome

Dispenzieri

Kyle

Lacy

et al. 2003

Blood

712

806

View full text Add to dashboard Cite

show abstract

“…Impotence (89 %) and gynecomastia (12 %) were common findings in male patients [ 13 ]. Sasano et al reported the first case that showed an improvement in gonadotropin secretion after corticosteroid therapy [ 14 ]. After three months of corticosteroids treatment, the 49-year-old male patient showed an improvement in danadotropin secretion but no considerable change in the secretion of the other hormones.…”

Section: Discussionmentioning

confidence: 99%

Improvement of sexual function in POEMS syndrome after combination therapy of Lenalidomide and dexamethasone

Yang

Cai

et al. 2016

Orphanet J Rare Dis

View full text Add to dashboard Cite

BackgroundPOEMS syndrome is a rare paraneoplastic syndrome due to an underlying plasma cell neoplasm. Hypogonadism is the most common endocrine abnormality in POEMS syndrome. There is no data about improvement of hypogonadism and sexual dysfunction after appropriate treatment of POEMS syndrome so far. In this single-center prospective study, the efficacy of low-dose lenalidomide and dexamethasone combination therapy in the improvement of sexual and gonadal function in POEMS syndrome was evaluated.ResultsThirty-five patients with newly diagnosed POEMS syndrome were treated with Lenalidomide (10 mg daily for 21 days) and dexamethasone (40 mg once per week) for 12 cycles. The international index of erectile function (IIEF) in male patients, the female sexual function index (FSFI) in female patients, total testosterone, estradiol and vascular endothelial growth factor (VEGF) levels were reviewed. Sexual dysfunction was reported in 88.8 % (24/27)male and 90.9 % (10/11) female patients. 62.9 % (17/27) male and 25.0 % (3/12) female patients had hypogonadism. After 12-month treatment, the mean total FSFI score had increased from 17.1 ± 7.2 to 23.7 ± 7.2(p < 0.05). The arousal, orgasm and sex pain domains had been improved significantly. The mean IIEF scores had increased from 12.9 ± 13.0 to 20.5 ± 18.4 (p < 0.05). Erectile function, sexual desire and intercourse satisfaction had improved significantly at the end of treatment. No association between VEGF levels and sexual function improvement was found in both genders.ConclusionCombination therapy with low-dose lenalidomide plus dexamethasone is successful in improving sexual function in POEMS syndrome.

show abstract